Vesica Health Builds Data for Follow-On Applications of Bladder Cancer Test

With plans in place to launch a urine-based molecular test for bladder cancer detection next month, Vesica Health is also gearing up to validate a second application in post-treatment patient surveillance.

In that vein, European researchers recently published a study in the journal European Urology Open Science concluding that while further validation in larger cohorts is warranted, the company's AssureDx test has the potential to reduce the use of cystoscopies in patients who have had radiation treatment for muscle-invasive bladder cancer.